Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old
Abstract
A subunit vaccine for respiratory syncytial virus (RSV) consisting of purified fusion glycoprotein (designated PFP-1) was tested in children 24 to 48 months old. Two doses of 20 micrograms (n = 13) and 50 micrograms (n = 10) were compared with a saline (n = 24) placebo control group. Local and syste …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
female
male
Child
preschool
Clinical Trial
Randomized Controlled Trial
follow-up studies
Cohort Studies
neutralization tests
respiratory syncytial virus infections / prevention & control*
enzyme-linked immunosorbent assay
viral fusion proteins / immunology*
p r paradiso
human / immunology*
human / isolation & purification
respiratory syncytial virus
vaccination*
pmid:7808848
doi:10.1097/00006454-199409000-00008
s w hildreth
d h smith
Access
Citation
ID:
117149
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
117149
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet